Viatris Inc
Change company Symbol lookup
Select an option...
VTRS Viatris Inc
MITO Stealth BioTherapeutics Corp
SHOP Shopify Inc
CHMR Chimera Energy Corp
QTRX Quanterix Corp
MSEX Middlesex Water Co
EQIX Equinix Inc
PEAK Healthpeak Properties Inc
TAL TAL Education Group
CPLP Capital Product Partners LP
Go

Health Care : Pharmaceuticals | Mid Cap Value
Company profile

Viatris Inc. is a global healthcare company. The Company has four segments: Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets segment comprises its operations primarily in North America and Europe. Greater China segment includes its operations in China, Taiwan and Hong Kong. JANZ segment reflects its operations in Japan, Australia and New Zealand. Emerging Markets segment encompasses its presence in approximately 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as its anti-retroviral franchise. Its portfolio comprises approximately 1,400 approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. It operates approximately 40 manufacturing sites worldwide, which produces oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.

Closing Price
$9.21
Day's Change
0.49 (5.62%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.21
Day's Low
8.79
Volume
(Below Average)
Volume:
8,796,084

10-day average volume:
10,546,291
8,796,084

Company Profile

Viatris Inc. is a global healthcare company. The Company has four segments: Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets segment comprises its operations primarily in North America and Europe. Greater China segment includes its operations in China, Taiwan and Hong Kong. JANZ segment reflects its operations in Japan, Australia and New Zealand. Emerging Markets segment encompasses its presence in approximately 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as its anti-retroviral franchise. Its portfolio comprises approximately 1,400 approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. It operates approximately 40 manufacturing sites worldwide, which produces oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.

Valuation Ratios

Price/Earnings (TTM)
13.63x
Price/Sales (TTM)
0.60x
Price/Book (MRQ)
0.52x
Price/Cash Flow (TTM)
2.59x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend

Short Interest

September 2022
Current Month
27.4M
Previous Month
23.7M
Percent of Float
2.26%
Days to Cover
2.8068 Days

Share Information

VTRS is in a share class of common stock
Float
1.2B
Shares Outstanding
1.2B
Institutions Holding Shares
1,309
73.10%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Robert J. CouryChmn.
  • Rajiv MalikPres.
  • Michael GoettlerCEO
  • Mark W. Parrish
  • Sanjeev NarulaCFO

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.